Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;22(8):1079-1086.
doi: 10.1111/ddg.15432. Epub 2024 Jun 25.

Mogamulizumab-associated rash - Case series and review of the literature

Inga Hansen  1 , Finn Abeck  1 , Anne Menz  2 , Stefan W Schneider  1 , Nina Booken  1
Affiliations
Review

Mogamulizumab-associated rash - Case series and review of the literature

Inga Hansen et al. J Dtsch Dermatol Ges. 2024 Aug.

Abstract

Mogamulizumab, a monoclonal antibody directed against CC chemokine receptor 4, is approved as a second-line treatment of mycosis fungoides and Sézary syndrome. One of the most common side effects is mogamulizumab-associated rash (MAR), which can present in a variety of clinical and histological types. Clinically, it can be difficult to differentiate between MAR and progression of the underlying disease, so histological examination is crucial for clinicopathological correlation. Current data analyses suggest that MAR is more common in patients with Sézary syndrome and is associated with a significantly better response to treatment, making the distinction from disease progression particularly important. The management of MAR depends on its severity, and therapy may need to be paused. This article presents three cases from our clinic and reviews the current literature on MAR. It emphasizes the importance of understanding MAR in the management of patients with cutaneous lymphomas.

Keywords: cutaneous t cell lymphoma; mogamulizumab; mogamulizumab-associated rash; mycosis fungoides; sézary syndrome.

PubMed Disclaimer

References

REFERENCES

    1. Dippel E, Assaf C, Becker JC, et al. S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021. J Dtsch Dermatol Ges. 2022;20(4):537‐554.
    1. Kim YH, Bagot M, Pinter‐Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T‐cell lymphoma (MAVORIC): an international, open‐label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192‐1204.
    1. Assaf C, Dobos G, Zech IM, et al. Epidemiology of mature T/NK‐cell lymphomas in Germany ‐ A representative cross‐sectional study based on SHI claims data. J Dtsch Dermatol Ges. 2023;21(11):1320‐1327.
    1. Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti‐CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2015;21(2):274‐285.
    1. Bonnet P, Battistella M, Roelens M, et al. Association of autoimmunity and long‐term complete remission in patients with Sezary syndrome treated with mogamulizumab. Br J Dermatol. 2019;180(2):419‐420.

Substances

LinkOut - more resources